Puma's Nerlynx unleashed to fight HER2+ breast cancer with 'best case' label

18th July 2017 Uncategorised 0

Puma Biotechnology grabbed its FDA approval for neratinib, the kinase inhibitor it’s been developing for HER2-positive breast cancer, but that doesn’t mean the newly dubbed Nerlynx will be roaring onto the market.

More: Puma's Nerlynx unleashed to fight HER2+ breast cancer with 'best case' label
Source: fierce